Skip to main content
. Author manuscript; available in PMC: 2023 May 1.
Published in final edited form as: Leukemia. 2022 Sep 20;36(11):2669–2677. doi: 10.1038/s41375-022-01704-z

Table 2.

Baseline characteristics according to DLIx (as categorical variable)

Total (N=171) High DLIx
(N=126)
Low DLIx
(N=45)
p-uni OR [95%CI] p-multi
DLBCL/HGBCL 101 (80) 32 (71) 0.22 - -
Age > 60 years 59 (47) 19 (42) 0.61 - -
Male 90 (71) 30 (67) 0.57 - -
ECOG PS 2–4 11 (9) 9 (20) 0.06 - -
Ann Arbor Stage III-IV 102 (81) 38 (84) 0.66 - -
Extra-nodal sites > 1 75 (60) 34 (76) 0.07 - -
IPI score 3–5 62 (49) 34 (76) 0.003 0.7 [0.2–1.8] 0.42
ANC low 23 (18) 12 (27) 0.28 - -
AMC low 6 (5) 5 (11) 0.16 - -
ALC low 86 (68) 45 (100) <0.001 0.03 [0.01–1.1] 1
Hemoglobin low 119 (94) 44 (98) 0.68 - -
PLT count low 59 (47) 29 (64) 0.06 - -
CRP high 80 (63) 33 (73) 0.27 - -
Ferritin high 91 (72) 35 (78) 0.56 - -
LDH high 78 (62) 40 (89) 0.10 - -
eGFR low 22 (17) 9 (20) 0.82 - -
Previous therapies > 2 98 (78) 37 (82) 0.67 - -
Bridging therapy: yes 56 (44) 30 (67) 0.02 0.5 [0.2–0.9] 0.04
Bridging: chemotherapy 35 (28) 17 (38) 0.26 - -
Refractory disease: yes 98 (78) 36 (80) 0.84 - -
Previous auto-SCT: yes 38 (30) 7 (16) 0.08 - -
Previous allo-SCT: yes 3 (2) 0 (0) 0.57 - -

DLIx, delta lymphocyte index; OR, odds ratio; CI, confidence interval; uni, univariate; multi, multivariate; DLBCL, diffuse large B-cell lymphoma; HGBCL, high grade B-cell lymphoma; PMBCL, primary mediastinal B-cell lymphoma; TFL, transformed follicular lymphoma; ECOG, European Cooperative Oncology Group; PS, performance status; IPI, international prognostic index; ANC, absolute neutrophil count; AMC, absolute monocyte count; ALC, absolute lymphocyte count; PLT, platelet; CRP, C-reactive protein; LDH, lactate dehydrogenase; eGFR, estimated glomerular filtration rate; auto, autologous; allo, allogeneic; SCT, stem cell transplant